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Highlights of Clinician/Scientist Translational
Discussion Session
Jackie Bickenbach, PhD1, Molly Kulesz-Martin, PhD2, Richard Clark, MD3 and Karin Scharffetter-Kochanek,
MD4
Discussion topic: Bridging the basic understanding of wound healing to clinical applications and therapeutic
development. How can we bridge the gap to the clinic? What are some of the obstacles to progress and how can
we approach and overcome them?
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The last session of the 54th Annual Montagna Symposium on
the Biology of Skin consisted of breakout discussion sessions
to highlight the areas of wound healing that could make the
transition between the laboratory bench and the bedside, and
to highlight areas that need more research. The discussion
leaders set the topics for discussion:
GROUP 1. IS THE INFLAMMATORY RESPONSE
NECESSARY?
Inflammation exists to protect and defend wounds
against bacterial invasion. In the real world, wounds
can become contaminated. However, in the laboratory
setting, most wound models are sterile. Thus, to address
this question, we will need more natural wound models.
We would never suggest in the clinic to deplete all
the inflammatory cells. One thing upon which we can
all agree is that chronic inflammation is not going to
help. Persistent inflammation kills. We could apply antibiotic
to kill all the bacteria in a child in the hospital but how
can we apply this to a chronic wound. An essential point
is the underlying disease. Young and/or healthy people do
not get chronic wounds. Chronic wounds occur with
underlying disease. What about some chronic wounds
that do not exhibit acute inflammation or blood vessels?
Should we infect our laboratory models to make them more
realistic?
Timing is essential. Evolutionarily, tissues need a
fast inflammatory response to survive, but this response
needs to be turned down for healing. Inflammation may
be critical in determining the healing capacity of wounds.
In chronic wounds, the amount of bacterial is critical;
too much or too little may lead to chronic wound failure.
What cells bring in the inflammatory cells: fibroblasts,
epithelial cells? Alternatively, we do not need a cell, as
matrix fragments act as chemoattractants. Every cell can be
proinflammatory. Damaged cells, leakiness, and factors such
as IL-1 attract leukocytes. By the same token, all cells can
engulf debris.
In the clinic, we cannot eliminate inflammation, but we
could target inflammatory cells and tell them to leave or to
shut down, selectively depleting immune cells or inflamma-
tory molecules, for example, V-cam. This specific targeting
could aid in healing chronic wounds, if we knew which
molecules to target and when to target them.
GROUP 2. CAN TRANSPLANTATION OF STEM CELLS
HELP TO HEAL CHRONIC WOUNDS?
The primary goal is to choose the most appropriate model.
Most models use punch biopsies, which yield a large round
wound, whereas clinically, most wounds are incisional.
Delivery of stem cells to punch wounds may be problematic
because the center of the wound contains too many
proteases. A matrix holding the cells could be used to deliver
the cells and other wound-healing factors. Delivery of growth
factors and cytokines in the correct amount and order could
be sufficient to heal the wounds, but may not prevent
recurrence. Does use of stem cells help prevent recurrence of
the wound? It may be that delivery of sequential growth
factors/cytokines will be required to assist survival of the stem
cells. The last point is the model. Current mouse models do
not recapitulate chronic wounds. Thus, chronic wound in
vitro models may need to be developed.
GROUP 3. WHAT PREVENTS RE-EPITHELIALIZATION
AND MODULATION OF WOUNDS?
In general, when wounds do not re-epithelialize, the edge of
the wound is bulbous, but contains proliferative keratino-
cytes. Re-epithelialization does not need inflammatory cells.
In the lung, there is healing without inflammation. Thus, lack
of wound closure is likely owing to underlying matrix/wound
bed factors, such as proteases. Clinically, these wounds must
be debrided to rid the wound of denatured collagen and
fibronectin. It is believed that too much inflammatory
response is the main problem. However, there must be some
response to activate release of metalloproteinases, which are
needed for cell migration.
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It may be that each individual wound is unique. If so, we
will need to design a therapy to address each condition. For
example, large wounds could be covered by a matrix with the
appropriate growth and migration factors. This would allow
the epithelial cells to close the wound.
GROUP 4. WHAT IS NECESSARY FOR EXTRACELLULAR
MATRIX REMODELING AND SCAR PREVENTION?
The differences in scarring between the skin and the oral
mucosa need to be explored. Why does the oral mucosa not
scar? It may be temporal in nature. The oral mucosal cells
proliferate and migrate more rapidly than skin cells. It may be
the orientation of collagen fibrils and how fibroblasts align
these. Also, differences in aging effects between skin and oral
mucosa are unknown. We need to ensure that during wound
closure, both collagen types I and III are placed appropriately
in the wound. Scars are primarily collagen type I only. There
is also a need to understand how anti-scarring agents, such as
IL-10/tubuloglomerular feedback-b, work. Critical is expand-
ing research to different types of scarring (hypertrophic,
keloid) and defining which animal models are most informa-
tive for each (scarring in mouse versus ‘‘red dog’’ pig models;
lack of scarring in fetal and mucosal wound models).
A critical obstacle perceived in the progress to the
clinic is the restriction of end points currently recognized
by the Food and Drug Administration for testing new
drugs. Expanding those end points could lead to progress.
Such end points include improving the quality of granulation
tissue, or reducing scarring, and partial wound closure rather
than full wound closure. Some end points may not have good
animal models, and approval for clinical biopsies may
be appropriate and should be considered. In the real world,
we will need to deal with issues of protocols for multiple
drug application and wound care nursing. Particularly
challenging in this regard are the prospects that treatments
will be different for each day of acute wound care and that
chronic wound treatment occurs for the most part without
nursing care.
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